ATHE: Total Utang marang Modal Alterity Therapeutics Ltd

Logo perusahaan publik Alterity Therapeutics (ATHE)

The price indicator on the Alterity Therapeutics (ATHE) chart demonstrates a debt-to-equity ratio of 0.00. Alterity Therapeutics (ATHE) minimizes internal costs by outsourcing production and testing to third-party contractors. The business currently relies on raised capital to develop drugs for rare brain pathologies. The success of current tests will provide the company with exceptional demand due to the lack of available therapy methods in this niche.

ATHE - Total Utang marang Modal Alterity Therapeutics Ltd ing rentang 04.07.2022 - 31.10.2026

Rincian metrik lan analitis perusahaan Alterity Therapeutics Limited (ATHE)

- rega lan prakiraan konsensus rega:
Bagan rega Alterity Therapeutics Ltd.|ATHE - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Alterity Therapeutics|ATHE - Total Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham Alterity Therapeutics|ATHE - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku alteritytherapeutics.com|ATHE - Nilai Agregat Aset
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Alterity Therapeutics|ATHE - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Alterity Therapeutics Ltd.|ATHE - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Alterity Therapeutics|ATHE - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Alterity Therapeutics|Rasio cepet alteritytherapeutics.com
- statistik bathi lan rasio pasar:
ATHE - Penghasilan resik perusahaan
Analisis dhasar perusahaan:ATHE, Alterity Therapeutics
Barang utama Alterity Therapeutics Limited

The total debt-to-equity ratio measures the proportion of borrowed funds within the financing structure, determining the business's level of dependence on external creditors relative to its own equity. By analyzing the debt-to-equity leverage chart, an investor assesses the financial resilience of Alterity Therapeutics (ATHE), which is critical for ensuring the long-term trials of the ATH434 drug for the treatment of rare neurological pathologies.

Pesaing wigati

Utang marang Ekuitas Biogen|Rasio Utang marang Ekuitas NBIX (Neurocrine)|Total Utang marang Modal RGC|AXSM - Utang marang Modal|ACADIA Pharmaceuticals - Rasio Total Utang marang Ekuitas|Total Utang marang Modal xenon-pharma.com XENE|VKTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Utang marang Ekuitas|Utang marang Modal Denali Corp (DNLI)|HRMY (Harmony Biosciences) - Total Utang marang Modal|Total Utang marang Modal biohavenpharma.com|Utang marang Ekuitas Amylyx Pharmaceuticals, Inc. (AMLX)|Utang marang Ekuitas TRVI (Trevi Therapeutics Inc)|Praxis Medicines - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal AVXL (Anavex Life Sciences Corp)|CeriBell, Inc. - Total Utang marang Modal|Utang marang Modal Prothena Corporation PLC|alector.com (ALEC) - Utang marang Ekuitas|Annexon Biosciences - Rasio Kabeh Utang marang Dana Pribadi|OMER (Omeros Corp) - Total Utang marang Modal|Neurogene Therapeutics (NGNE) - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas ACIU (AC Immune)|Utang Agregat marang Modal VYGR|Neumora Therapeutics, Inc. - Rasio Total Utang marang Ekuitas|Scilex Holding (SCLX) - Utang marang Modal|TVGN: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ACOG (Alpha Cognition)|CGTX (Cognition Therapeutics) - Rasio Total Utang marang Ekuitas|IKT: Utang Agregat marang Modal|SAVA (Cassava Sciences) - Total Utang marang Modal|ASRT: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal COYA|VTGN - Utang marang Modal|Utang marang Ekuitas Ovid Therapeutics OVID|Rasio Kabeh Utang marang Dana Pribadi ABOS|CervoMed - Total Utang marang Modal|CLNN - Total Utang marang Modal|pepgen.com (PEPG) - Utang marang Ekuitas|Utang Agregat marang Ekuitas JUNS (Jupiter Neurosciences, Inc.)|RLMD (Relmada Therapeutics) - Total Utang marang Modal|Utang marang Modal annovisbio.com ANVS|Rasio Total Utang marang Ekuitas GRCE (Grace Therapeutics, Inc.)|Total Utang marang Modal Firefly Neuroscience, Inc. (AIFF)|Klotho Neurosciences - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal NRSN (NeuroSense Therapeutics Ltd)|Reviva Pharmaceuticals - Total Utang marang Modal|Koefisien Total Utang marang Modal MetaVia Inc MTVA|NRXS: Total Utang marang Modal|Rasio Total Utang marang Ekuitas Helius Medical Technologies|Utang marang Ekuitas Passage Bio Inc.|Neuphoria (NEUP) - Koefisien Total Utang marang Modal|Total Utang marang Modal NERV|Total Utang marang Modal athira.com (ATHA)|Addex Therapeutics Ltd - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal ALZN (Alzamend Neuro Inc.)|Cyclerion - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi PTIX (Protagenic Therapeutics)|KTTA: Total Utang marang Modal|Utang marang Modal Cortigent (CRGT)|Utang marang Ekuitas Avenue Therapeutics, Inc.|Rasio Utang marang Ekuitas BCLI (Brainstorm Cell Therapeutics Inc.)|Total Utang marang Modal CARA|CHRO - Utang marang Modal|Eliem Therapeutics Inc. - Rasio Total Utang marang Ekuitas|Total Utang marang Modal Intra-Cellular Therapies Inc. ITCI|LBPH - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi MRNS (Marinus Pharmaceuticals Inc)|NKGen (NKGN) - Utang marang Ekuitas|Utang marang Modal NeuroBo Pharma (NRBO)|SAGE (Sage Therapeutics, Inc.) - Total Utang marang Modal|Total Utang marang Modal synaptogen.com|Utang marang Ekuitas Trevena (TRVN)|Utang marang Ekuitas VIGL (vigilneuro.com)|Anew Medical - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal CERE (Cerevel Corp)